dol-A-se-tron

• PO: Prevention of nausea and vomiting associated with emetogenic chemotherapy.

• Blocks the effects of serotonin at receptor sites (selective antagonist) located in vagal nerve terminals and in the chemoreceptor trigger zone in the CNS.

• Decreased incidence and severity of nausea/vomiting associated with emetogenic chemotherapy or surgery.

Absorption: Well absorbed but rapidly metabolized to hydrodolasetron, the active metabolite.

Distribution: Unknown.

Metabolism/Excretion: 61% of hydrodolasetron is excreted unchanged by the kidneys.

Half-life: Hydrodolasetron — 8.1 hr (shorter in children).

Contraindicated in:

• Hypersensitivity
• Congenital long QT syndrome
• Complete heart block (unless pacemaker present).

Use Cautiously in:

• Patients with risk factors for cardiac conduction abnormalities (underlying structural heart disease, sick sinus syndrome, atrial fibrillation and slow ventricular rate, myocardial ischemia, concurrent beta-blocker, verapamil, diltiazem, or antiarrhythmic therapy)
• Hypokalemia, hypomagnesemia, concurrent therapy with diuretics, or history of cumulative high-dose anthracycline therapy
• Geri: ↑risk for cardiac conduction abnormalities
• OB: Lactation: Safety not established.

CV: CARDIAC ARREST, TORSADE DE POINTES, VENTRICULAR ARRHYTHMIAS, bradycardia, heart block, hypertension, hypotension, PR interval prolongation, QRS interval prolongation, QT interval prolongation, tachycardia.

GI: diarrhea, dyspepsia.

GU: oliguria.

Derm: pruritus.

Neuro: headache (increased in cancer patients), dizziness, fatigue, syncope.

Misc: SEROTONIN SYNDROME, chills, fever, pain.

Drug-Drug:

• Concurrent diuretic or antiarrhythmic therapy or cumulative high-dose anthracycline therapy may ↑ risk of conduction abnormalities.
• Blood levels and effects of hydrodolasteron are ↑ by atenolol and cimetidine.
• Blood levels and effects of hydrodolasetron are ↓ by rifampin.
• ↑risk of QT interval prolongation with other agents causing QT interval prolongation.
• Drugs that affect serotonergic neurotransmitter systems, including SSRIs, SNRIs, tricyclic antidepressants, MAOIs, fentanyl, lithium, buspirone, tramadol, methylene blue, and triptans↑ risk of serotonin syndrome

Prevention of Chemotherapy-Induced Nausea/Vomiting

• PO (Adults): 100 mg given within 1 hr before chemotherapy.
• PO (Children 2–16 yr): 1.8 mg/kg given within 1 hr before chemotherapy (not to exceed 100 mg).

• PO: Administer within 1 hr before chemotherapy.

Anzemet

Therapeutic Classification: antiemetics

Pharmacologic Classification: five ht3 antagonists

• Tablets: 50 mg; 100 mg;

(antiemetic effect)

• Assess patient for nausea, vomiting, abdominal distention, and bowel sounds before and after administration.
• Monitor ECG in patients with HF, bradycardia, underlying heart disease, renal impairment, and elderly patients.

• Monitor serum potassium and magnesium prior to and periodically during therapy.

• Imbalanced nutrition: less than body requirements (Indications).

• Explain purpose of dolasetron to patient.
• Advise patient to notify health care professional if nausea or vomiting occurs.
• Advise patient to notify health care professional if symptoms of abnormal heart rate or rhythm (racing heart beat, shortness of breath, dizziness, fainting) occur.

• Prevention of nausea and vomiting associated with emetogenic cancer chemotherapy.

NDC Code^*

• 30698- Validus Pharmaceuticals LLC
  • 30698-120- ANZEMET
    • 30698-120-05- 5 TABLET, FILM COATED in 1 BOTTLE (30698-120-05)

• 30698- Validus Pharmaceuticals LLC
  • 30698-121- ANZEMET
    • 30698-121-05- 5 TABLET, FILM COATED in 1 BOTTLE (30698-121-05)